Cancer News and Research

Latest Cancer News and Research

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Scientists have generated hundreds of new leads in the fight against the H1N1 flu pandemic, according to two new studies published online December 17th in the journal Cell, a Cell Press publication.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

ARIAD Pharmaceuticals, Inc. today announced the completion of patient enrollment in its pivotal, Phase 3 clinical trial of oral ridaforolimus, its investigational mTOR inhibitor, in patients with metastatic soft-tissue and bone sarcomas.

18 Dec 2009

Calorie-intake restriction can benefit longevity and help prevent cancer

Researchers from the University of Alabama at Birmingham (UAB) have discovered that restricting consumption of glucose, the most common dietary sugar, can extend the life of healthy human-lung cells and speed the death of precancerous human-lung cells, reducing cancer's spread and growth rate.

18 Dec 2009

Triad Isotopes enters into agreement to acquire the U.S. radiopharmacy network

Triad Isotopes, Inc., a portfolio company of Parthenon Capital Partners, today announced that it has entered into an agreement to acquire the U.S. radiopharmacy network currently owned and operated by Covidien, a leading global healthcare products company based in Dublin, Ireland.

18 Dec 2009

Scientists discover new model to asses homeostatic relationships between body substances

The Center for Modeling Optimal Outcomes, LLC, a New Jersey based think tank focused on the application of neuroscience in business, inadvertently discovered a scientifically verifiable model for assessing homeostasis (balance) between substances in the body.

18 Dec 2009

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

Agendia, a world leader in molecular cancer diagnostics, announced today that the US Food and Drug Administration (FDA) cleared its MammaPrint breast cancer recurrence test for all ages. MammaPrint is the only FDA-cleared breast cancer recurrence test available to patients and physicians.

17 Dec 2009

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

17 Dec 2009

Shift working may accelerate metabolic syndrome

Shift work exposures can accelerate metabolic syndrome (MetS) development among the large population of middle-aged males with elevated alanine aminotransferase (ALT). Elevated serum alanine aminotransferase (e-ALT) is a common abnormality of health examinations in middle-aged working populations.

17 Dec 2009

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Revolutions Medical Corporation, producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced today that recent mass media reports that CT scans cause cancer could rapidly elevate MRI as the technology of choice for musculoskeletal scans and more.

17 Dec 2009

Reform issues in play: Selling insurance across state lines, Medicare’s doughnut hole

News outlets report on some of the major health policy issues being considered by the Senate, including a proposal to let insurers sell plans across state lines and an effort to close the Medicare "doughnut hole."

17 Dec 2009

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

AlphaRx Inc. announced today that it has signed an agreement that provides long-term supply of the active pharmaceutical ingredient (API) for ARX1088, an orally active interferon inducer intended for the adjunctive treatment of Hepatitis in China and other emerging markets. Under the agreement, Venturepharm will be the primary supplier of AlphaRx's worldwide requirements for the compound.

17 Dec 2009

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

John Howell, CEO of Arrayit Diagnostics, Inc., a majority-owned subsidiary of Arrayit Corporation (OTC Bulletin Board: ARYC), today formally commented on the anticipated timeline for commercialization of its microarray-based OvaDx(TM) Pre-Symptomatic Ovarian Cancer Blood Test, which is currently advancing through late-stage development - the rights to which have been assigned exclusively to the Company by Arrayit Corporation.

17 Dec 2009

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

David Allan, Chairman and CEO of YM BioSciences Inc. and Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced the signing of an agreement under which Therapure Biopharma will provide fill and finish services for nimotuzumab, the humanized monoclonal antibody licensed to YM's majority-owned Canadian subsidiary, CIMYM BioSciences Inc., by the Centre of Molecular Immunology (CIM).

17 Dec 2009

Avecia Biologics to be acquired by Merck

Merck & Co. Inc., (operating in the United Kingdom as MSD) and Avecia Investments Limited today announced that they have entered into a definitive agreement by which Merck will acquire the biologics business of the Avecia group through a Merck affiliate (Merck Sharp & Dohme (Holdings) Limited or "MSD"). Avecia Biologics is a contract manufacturing organization with specific expertise in microbial-derived biologics. Financial details of the transaction were not disclosed.

17 Dec 2009

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

BioDelivery Sciences International, Inc. announced that the primary efficacy endpoint was achieved in the Company’s Phase 2 pain study assessing the efficacy and safety of BEMA Buprenorphine. The positive results follow BDSI’s March 2009 announcement of favorable Phase 1 study results.

17 Dec 2009

E Cigarettes National: Special interest groups have no legitimate argument against the cigarette

Over the last few weeks there has been an increase of the amount of scare language that is used by e cigarette opposition in an attempt to scare the population concerning the electronic cigarette. Many are questioning the tactics of these groups when the evidence clearly shows that the product is indeed a safer alternative to tobacco according to several studies, lab reports and opinions from top medial and harm reduction specialist around the world.

17 Dec 2009

LA dentist offers special service packages for Christmas season

To celebrate Christmas and the holiday season, Los Angeles dentist Dr. Neda Naim is thanking new patients for scheduling appointments by providing specials on selected services throughout December.

17 Dec 2009

Advances in DNA-sequencing technology help identify your personal genome

What secrets about your risk for diseases are written in your own personal "Book of Life" - the 30,000 or so genes that make you you? Advances in DNA-sequencing technology are bringing closer the day when it will be more economical for consumers to get an answer to that question, and others, by ordering up the deciphering of their entire genetic endowment - their "personal genome."

17 Dec 2009

Cancer News and Research

Latest Cancer News and Research

Comprehensive approaches to understand the interaction of H1N1 strains with human cells

Phase 2 clinical study of STA-9090 in NSCLC initiated

ARIAD Pharmaceuticals completes enrollment of patients for Phase 3 clinical trial of ridaforolimus

Calorie-intake restriction can benefit longevity and help prevent cancer

Triad Isotopes enters into agreement to acquire the U.S. radiopharmacy network

Scientists discover new model to asses homeostatic relationships between body substances

FDA clears Agendia's MammaPrint breast cancer recurrence test for all ages

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Shift working may accelerate metabolic syndrome

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

RevMed MRI Technology converts standard grayscale scans to segmented, 3D, color images

Reform issues in play: Selling insurance across state lines, Medicare’s doughnut hole

AlphaRx, Venturepharm sign supply agreement for ARX1088's API

Arrayit Diagnostics to begin marketing its OvaDx Pre-Symptomatic Ovarian Cancer Blood Test in 2010

Therapure Biopharma to fill/finish nimotuzumab at its Canadian GMP certified fill suite

Avecia Biologics to be acquired by Merck

BDSI's BEMA Buprenorphine Phase 2 study meets primary efficacy endpoint

E Cigarettes National: Special interest groups have no legitimate argument against the cigarette

LA dentist offers special service packages for Christmas season

Advances in DNA-sequencing technology help identify your personal genome

Cancer Research - Second Edition eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in